Thyroid Cancer Genetics: Multiple Endocrine Neoplasia Type 2, Non-Medullary Familial Thyroid Cancer, and Familial Syndromes Associated with Thyroid Cancer

Surgical Oncology Clinics of North America

Volumn 18, Issue 1, 2009, Pages 39-52

  Richards, Melanie L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Familial thyroid cancer; Medullary thyroid cancer; Multiple endocrine neoplasia; Thyroid genetics

Indexed keywords

SORAFENIB; VANDETANIB;

ADENOMATOUS POLYP; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CARNEY COMPLEX; COWDEN SYNDROME; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL AMYLOIDOSIS; GANGLIONEUROMA; GARDNER SYNDROME; GENETIC SCREENING; GENOTYPE; HIRSCHSPRUNG DISEASE; HISTOPATHOLOGY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PHEOCHROMOCYTOMA; PRIMARY HYPERPARATHYROIDISM; REVIEW; THYROID CANCER; THYROIDECTOMY; TURCOT SYNDROME; WERNER SYNDROME;

DNA MUTATIONAL ANALYSIS; GENETIC SCREENING; GENOTYPE; GERM-LINE MUTATION; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASTIC SYNDROMES, HEREDITARY; PHENOTYPE; RISK FACTORS; THYROID NEOPLASMS;

EID: 56849117077     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.08.002     Document Type: Review

References (58)

1. American Cancer Society. Cancer facts and figures 2007 (2007), American Cancer Society, Atlanta (GA)
2. National Cancer Institute. Incidence: thyroid cancer (2007), National Cancer Institute, SEER, Bethesda (MD)
3. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83 12 (1998) 2434-2436
4. Grossman R.F., Tu S.H., Duh Q.Y., et al. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg 130 (1995) 892-899
5. Sipple J.H. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med (1961) 163-166
6. Steiner A.L., Goodman A.D., and Powers S.R. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism, and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47 (1968) 371-409
7. Chong G.C., Beahrs O.H., Sizemore G.W., et al. Medullary carcinoma of the thyroid gland. Cancer 35 (1975) 695-704
8. Farndon J.R., Leight G.S., Dilley W.G., et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 (1986) 278-281
9. Mathew C.G., Chin K.S., Easton D.F., et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328 (1987) 527-528
10. Takahashi M., and Cooper G.M. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 42 (1985) 581-588
11. Ishizaka Y., Itoh F., Tahira T., et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene (1989) 1519-1521
12. Eng C., Smith D.P., Mulligan L.M., et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3 (1994) 237-241
13. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
14. Arighi E., Borrello M.G., and Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev (2005) 441-467
15. Ponder B.A.J. Multiple endocrine neoplasia type 2. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). The metabolic and molecular basis of inherited disease. 8th edition (2001), McGraw-Hill, New York 931-942
16. Jimenez C., and Gagel R.F. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res (2004) S150-S157
17. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5667
18. Verdy M., Weber A.M., Roy C.C., et al. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1 4 (1982) 603-607
19. Frilling A., Becker H., and Roeher H.D. Unusual features of multiple endocrine neoplasia. Henry Ford Hosp Med J 40 3-4 (1992) 253-255
20. Fialkowski E.A., DeBenedetti M.K., Moley J.F., et al. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg 43 1 (2008) 188-190
21. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416
22. O'Riordain D.S., O'Brien T., Crotty T.B., et al. Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 118 6 (1995) 936-942
23. O'Riordain D.S., O'Brien T., Weaver A.L., et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116 6 (1994) 1017-1023
24. Scheuba C., Kaserer K., Bieglmayer C., et al. Medullary thyroid microcarcinoma recommendations for treatment-a single center experience. Surgery 142 (2007) 1003-1010
25. Scollo C., Baudin E., Travagli J.P., et al. Rationale for central and bilateral node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88 (2003) 2070-2075
26. de Groot J.W., Links T.P., Sluiter W.J., et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery. Head Neck 29 (2007) 857-863
27. National Comprehensive Cancer Network. Practice guidelines in oncology. Thyroid cancer 2 (2008)
28. Stulak J.M., Grant C.S., Farley D.R., et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141 5 (2006) 489-494 [discussion: 494-6]
29. Kouvaraki M.A., Shapiro S.E., Fornage B.D., et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134 6 (2003) 946-954 [discussion: 954-5]
30. Gertner M.E., and Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol 5 (2004) 315-325
31. Bethanis S., Koutsodontis G., Palouka T., et al. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones 6 2 (2007) 152-156
32. Plaza-Menacho I., Mologni L., Sala E., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282 40 (2007) 29232-29240
33. Alsanea O., and Clark O.H. Familial thyroid cancer. Curr Opin Oncol 13 (2001) 44-51
34. Takami H., Ozaki O., and Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg 131 (1996) 676
35. Frich L., Glattre E., and Akslen L.A. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer epidemiol Biomarkers Prev 10 (2001) 113-117
36. Sturgeon C., and Clark O.H. Familial nonmedullary thyroid cancer. Thyroid 15 6 (2005) 588-593
37. Triponez F., Wong M., Sturgeon C., et al. Does familial non-medullary thyroid cancer adversely affect survival?. World J Surg 30 5 (2006) 787-793
38. Malchoff C.D., Sarfarazi M., Tendler B., et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 85 (2000) 1758-1764
39. McKay J.D., Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69 (2001) 440-446
40. Bignell G.R., Canzian F., Shayeghi M., et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 61 (1997) 1123-1130
41. Canzian F., Amati P., Harach H.R., et al. A gene predisposing to familial thyroid tumors with cell oxphilia maps to chromosome 19p13.2. Am J Hum Genet 63 (1998) 1743-1748
42. Prazeres H.J., Rodrigues F., Soares P., et al. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Fam Cancer 7 2 (2008) 141-149
43. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 (1990) 557-563
44. Alberti L., Carniti C., Miranda C., et al. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 295 (2003) 168-186
45. Ichihara M., Murakumo Y., and Takahashi M. RET and neuroendocrine tumors. Cancer Lett 204 (2004) 197-211
46. Santoro M., Melillo R.M., Carlomagno F., et al. Minireview: RET: normal and abnormal functions. Endocrinology 145 (2004) 5448-5451
47. Nehlin J.O., Skovgaard G.L., and Bohr V.A. The Werner syndrome. A model for the study of human aging. Ann NY Acad Sci 908 (2000) 167-179
48. Oshima J. The Werner syndrome protein: an update. Bioessays 22 (2000) 894-901
49. Ishikawa Y., Sugano H., Matsumoto T., et al. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer 85 (1999) 1345-1352
50. Luk G.D. Diagnosis and therapy of hereditary polyposis syndromes. Gastroenterologist 3 (1995) 153-167
51. Sugg S.L., Ezzat S., Rosen I.B., et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83 11 (1998) 4116-4122
52. Cetta F., Montalto G., Baldi C., et al. Germ-line mutations of the APC gene in patients with FAP associated thyroid carcinoma. Results from a European cooperative study. J Clin Endocrinol Metab 85 (2000) 286-292
53. Herraiz M., Barbesino G., Faquin W., et al. Prevalence of thyroid cancer familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5 (2007) 367-373
54. Tomoda C., Miyauchi A., Uruno T., et al. Cribiform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28 (2004) 886-889
55. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
56. Marsh D.J., Coulon V., Lunetta K.L., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7 (1998) 507-515
57. Carney J.A., and Young W.F. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist 2 (1992) 6-21
58. Stratakis C.A., Courcoutsakis N.A., Abati A., et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 82 (1997) 2037-2043